The Science

56 day randomised, double blind, placebo-controlled trial of 3 doses of Epiitalis® vs. placebo in patients with X-ray verified mild knee osteoarthritis.

• Three Epiitalis® groups: high dose (HD,320 mg bi-daily), mid-dose (MD,320 mg once-daily),
low dose (LD,160 mg once-daily).
• Placebo
• 235 participants

Primary endpoints:
Change in mild pain from Day 0 (baseline) to Day 56 (study end).

Exploratory endpoints:
Mild stiffness, General Health and Wellbeing and percentage of people with mild knee osteoarthritis, whose symptoms responded to Epiitalis® intervention.

At day 56 (study end) Epiitalis® intervention resulted in a 47% decrease in mild knee joint pain vs a 12.5% decrease in the placebo group.

Average patient pain score at Day 0 (baseline) was 7.5/10.

At study end, there was a clear differentiation in reduction of mild knee joint pain between the placebo and Epiitalis® group.

Reduction in mild knee joint pain with Epiitalis® intervention continued to increase with time over the 56-day study with maximal reduction observed at study end (day-56).

At day 56 (study end), General Health and Wellbeing of patients taking a daily dose of Epiitalis® was enhanced by 83% compared to just 4% in patients taking a placebo.

At day 56 (study end) Epiitalis® reduced mild stiffness, by approximately 50% in people with mild knee osteoarthritis vs 11.5% with Placebo.

On day 56, 80% of people with mild knee osteoarthritis experienced a reduction in symptoms (mild pain/stiffness)  due to Epiitalis® intervention vs only 10.9% in the placebo group.